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A B S T R A C T
Epilepsies can be caused by speciﬁc genetic anomalies or by non-genetic factors, but in many cases the
underlying cause is unknown.
Mutations in the SCN1A and SCN2A genes are reported in childhood epilepsies; in particular SCN1A
was found mutated in patients with Dravet syndrome and with generalized epilepsy with febrile
seizures plus (GEFS+).
In this paper we report a patient presenting with an atypical epileptic syndrome whose phenotype
partially overlaps both Dravet syndrome and benign familial neonatal-infantile seizures (BFNIS).
Array-CGH analysis suggested the presence of a mosaic duplication (about 12 Mb) at the level of
chromosome 2q23.3q24.3 involving SCN2A and SCN3A genes. Additional analyses (radiolabeled RFLP
and quantitative PCR) conﬁrmed the mosaicism of the duplication.
We suggest that the array-CGH analysis is mandatory for children presenting with epilepsy and
psycho-motor retardation even without dysmorphisms or other clinical features suggesting a speciﬁc
genetic/epileptic syndrome. The analysis must nevertheless be performed taking into account the
possibility of a mosaicism.
 2011 British Epilepsy Association. Published by Elsevier Ltd. All rights reserved.
Contents lists available at ScienceDirect
Seizure
jou r nal h o mep age: w ww.els evier . co m/lo c ate /ys eiz1. Introduction
Epilepsies are a group of heterogeneous neurological disorders
characterized by recurrent and unprovoked seizures due to an
abnormal electrical activity in the central nervous system.
While they can be caused by speciﬁc genetic anomalies
(cytogenetic abnormalities,1 single gene mutations2) and by
non-genetic factors (infections, stroke, head trauma and brain
tumors), in most cases the underlying cause is unknown.
Isolated epilepsy has been recently associated with mutations
in a number of genes, the majority of which encode ion channels or
receptors, including voltage-gated sodium, potassium, calcium,
and chloride channels and receptors for acetylcholine and Y-
aminobutyric acid (GABA).2–6
Mutations in the sodium channel genes (SCN1A and SCN2A)
have been identiﬁed in monogenic childhood epilepsies. SCN1A
mutations have been found in patients with generalized epilepsy
with febrile seizures plus (GEFS+) and with Dravet syndrome; the
latter typically presents with prolonged febrile convulsions in* Corresponding author. Tel.: +39 0498213572; fax: +39 0498211425.
E-mail address: maurizio.clementi@unipd.it (M. Clementi).
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doi:10.1016/j.seizure.2011.07.008infants at about 6 months of age and worsens during the second
year of life causing drug resistant seizures and cognitive and motor
skill deterioration. Mutations in SCN2A have been found in families
with benign familial neonatal-infantile seizures (BFNIS), a self-
limiting disorder generally presenting between 2 days and 7
months with a spontaneous remission of seizures at about 18
months and normal cognitive outcome. Shi et al.7 screened 59
patients with Dravet syndrome for mutations of SCN1A, SCN2A and
GABRG2 and found three missense SCN2A mutations. Mutations of
sodium channel SCN3A were recently found in a patient with
cryptogenic pediatric partial epilepsy.3 Functional analysis of
sodium channel mutations (SCN1A, SCN2A and SCN3A) revealed
that they are implicated in neuronal excitability suggesting that
they play a role in the pathogenesis of epilepsy.
We report a patient affected with infantile epilepsy associated
with mosaicism for a 12.01 Mb duplication of the long arm of
chromosome 2 including SCN2A and SCN3A genes.
2. Clinical report
The propositus is a Caucasian male who was referred to our
institute for evaluation of developmental delay and epilepsy. He was
born at 38 weeks of gestation via spontaneous vaginal delivery to
unrelated healthy parents following an uncomplicated pregnancy.vier Ltd. All rights reserved.
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(25th–50th centile), and head circumference was 34 cm (25th–50th
centile). At 3 months of age he presented with clusters of focal
seizures with secondary generalization. The electroencephalogram
(EEG) showed multifocal poly-spike activity and the brain magnetic
resonance imaging was unremarkable. The seizures were controlled
with carbamazepine and treatment was discontinued at 13 months
of age. The psychomotor development was mildly delayed during
the ﬁrst year of life. At two years of age, he presented with daily head
nodding and obtundation status associated with neurological
regression. Video-EEG showed atonic seizures, and a diagnosis of
myoclonic-astatic epilepsy was proposed. Sodium valproate suc-
cessfully controlled the seizures and, even though clumsiness
persisted, the child’s language improved. At ﬁve years of age, some
absences were noted by the parents and the EEG showed multiple
spikes at the vertex with normal background activity; the physical
examination did not document any signiﬁcant dysmorphisms. At
the moment, the patient is seven years old and seizure-free. Since
the family history was positive for epilepsy and febrile convulsions,
SCN1A mutations were excluded by sequence analysis and
multiplex ligation-dependent probe ampliﬁcation (MLPA). More-
over, an array-CGH analysis was performed because of persisting
clumsiness and cognitive impairment.
3. Materials and methods
3.1. DNA extraction
Genomic DNA of the proband and his parents was extracted
from peripheral blood using a High Pure PCR Template Preparation
Kit (Roche Diagnostics GmbH, Mannheim, Germany).
3.2. Array-CGH analysis
Molecular karyotyping was performed through array-CGH with
the Agilent Human Genome CGH Microarray Kit 244A, which
consists of 236,000 60-mer oligonucleotide probes covering the
entire genome with an overall median probe spacing of 8.9 kb
(7.4 kb in Refseq genes).
Brieﬂy, 500 ng of DNA from the test and a sex-matched pooled
normal reference (Promega, Madison, WI, USA) were double-
digested with RsaI (Promega) and AluI (Promega) for 2 h at 37 8C
according to the manufacturer’s protocol.
The digested samples were labeled by random priming using an
Agilent labeling kit (Agilent Technologies, Santa Clara, CA, USA)
according to the manufacturer’s instructions. Patient and reference
DNAs were labeled with Cy5-dUTP and Cy3-dUTP, respectively.
Labeled products were puriﬁed using Microcon YM-30 ﬁlter units
(Millipore, Billerica, MA, USA).
Patient and control DNAs were combined and mixed with Cot-1
DNA (Invitrogen) blocking agent and hybridization buffer follow-
ing the protocol provided by Agilent. After denaturation at 95 8C
and pre-annealing at 37 8C, hybridization was performed at 65 8C
with rotation for 24 h.
After two washing steps, the array was analyzed using an
Agilent scanner (G2505C) and Feature Extraction software
V.10.1.1.1. A graphical overview of the results was obtained using
DNA Analytics software V.4.0.76. DNA sequence information refers
to the public UCSC database [Human Genome Browser, March
2006, assembly hg18 (NCBI Build 36.1)].
3.3. Radiolabeled RFLP
The entire hypothetic duplicated region was screened using
NCBI dbSNP (http://www.ncbi.nlm.nih.gov/snp/) to ﬁnd a high-
frequency single nucleotide polymorphism (SNP) that can intro-duce/eliminate a consensus sequence for a restriction enzyme.
Only one SNP corresponding to the features described above was
found: rs582447.
A couple of primers were designed to amplify a 199 bp fragment
(forward: CATCAGTGGACAGGAATGGTT and reverse: CACCATTG-
GAGAATAAGACAGGA) encompassing a HindIII site.
The PCR product was then radiolabeled with a32PdCTP (Perkin
Elmer), using the ‘last cycle hot’ method.8
The radiolabeled products were subsequently digested over-
night using HindIII restriction endonuclease (New England
Biolabs) according to the manufacturer’s protocol and separated
by PAGE. Detection of radioactivity and image analysis were
performed as previously described.9
3.4. Quantitative PCR
Quantitative PCR, used to conﬁrm the duplication detected by
array-CGH analysis, was performed on a RotorGene 6000 (Corbett
Research, Mortlake, Australia) using Takara Ex Taq R-PCR custom
(Takara Bio Inc., Otsu, Shiga, Japan) and the same primers designed
for radiolabeled RFLP were used (see above).
The reaction was run in a ﬁnal volume of 25 ml, containing
100 ng genomic DNA, 1 PCR buffer, 1.5 mM MgCl2, 0.2 mM
dNTPs, 300 nM of each primer, 1.5 mM EvaGreen (Biotium,
Hayward, CA) 1.25 IU Taq DNA polymerase (Takara Bio). PCR
was performed in triplicate for each sample and cycling conditions
were: 95 8C 3 min and 40 cycles 95 8C 30 s, 57 8C 30 s, 72 8C 30 s.
A 280 base-pair DNA fragment within the NF1 gene (forward:
ATTCCTTCTGAAAACCAAGG and reverse: AAGGCAGACTGAGCTTA-
CAG) was used as a reference amplicon.
Gene dosage was determined using Comparative Quantitation
software (Corbett Research) which calculates the ampliﬁcation
rate on the basis of the increase in ﬂuorescence during the PCR
exponential phase and determines the take off point that is the last
point before the signal emerges from the noise level as described in
the 2002 technical bulletin ‘‘An explanation of the comparative
quantitation technique used in the Rotor-Gene analysis software’’
(M. Hermann, Corbett Research).
The slope of the line from the take off point until exponential
ampliﬁcation stops is used to calculate the ampliﬁcation efﬁciency.
The quantiﬁcation of test genes relative to a designated control
one was then calculated using the formula: (E)^[(control take-off
point)  (sample take-off point)] where (E) is the ampliﬁcation
efﬁciency.
The experiments were repeated ﬁve times and the average
comparative concentration in the gene tested was calculated.
4. Results
Array-CGH analysis detected a log ratio = 0.3 at the level of
chromosome 2q23.3q24.3 (154370122 bp–166384278 bp) sug-
gesting that there was a duplication of the region spanning about
12.01 Mb (Fig. 1). Since a non-mosaic duplication would have
given a log ratio of 0.58 (log2 3/2), a value of 0.3 means that 51% of
the cells carry the duplication (0.3/0.58) (Fig. 1).
Two different experiments – a Real-Time quantitative PCR and a
densitometric analysis of a radiolabeled RFLP – were carried out to
conﬁrm the array-CGH data.
A RFLP analysis on radiolabeled PCR was performed to conﬁrm
mosaicism of the duplication, to deﬁne its value, and to determine
the allele in which the alteration arose. The ‘‘last cycle hot’’
procedure avoids the formation of heteroduplexes which can lead
to imprecision in the quantitation of individual alleles. The unique
polymorphism situated in the region of interest resulting both
heterozygous in the patient and detectable by RFLP was tested. An
intra-lane comparison between the values obtained from cut and
Fig. 1. Array-CGH; graphical output of mosaic duplication in 2q23.3q24.3. (A) Chromosome view. (B) Gene view (the genes potentially involved in the described phenotype
are highlighted).
M. Vecchi et al. / Seizure 20 (2011) 813–816 815uncut bands (T and G, respectively), that stay for the fraction
representing the two different alleles in each single ampliﬁcation
(G + T = 1.00), were performed using a densitometric test. In a
normal heterozygous sample we observed the expected values of
about 50% (0.50) for each band. In the proband, the uncut band (G)
was about 70% (0.70) and the cut band (T) was about 30% (0.30) of
the total ampliﬁcation. These data indicate that the G-variant allele
was duplicated in about 40% (0.40) of the cells, and the formula
used to calculate it was:
G allele : 2a  0:5 þ ð1  aÞ  0:5 ¼ G
T allele : 1  ½2a  0:5 þ ð1  aÞ  0:5 ¼ T
where a is the fraction of cells with duplication.
These formulas describe the fraction of each single allele in a
heterozygous state. In this case, since the G fraction was 0.70, the a
value was 0.40 or 40% of the duplicate cells (in a normal
heterozygous state, the a value should be 0 and the G value
should be 0.50). The duplicate allele was found to be paternal, since
the patient’s father was homozygous for the G variant, while the
mother was heterozygous (G/T).
The result of Real-Time quantitative PCR was 1.222  0.118. A
sample with no duplication produces a value of 100% (1.00 or 2/2),
while an increased value of 50% (1.50 or 3/2) means that duplication
involves all the cells. The increment of 22.2% according to our data
indicates that 44% of the cells were involved in duplication (1.222 or
2.444/2).
5. Discussion
We reported the case of a child with atypical epileptic
syndrome: while the type of seizure, the drug response, and the
time of onset are similar to the ﬁndings observed in BFNIS, our
proband presented seizure recurrence at the age of two years with
intellectual disability and motor impairment, characteristic of the
Dravet syndrome.Array-CGH analysis suggested the presence of a mosaic
2q23.3q24.3 duplication (about 12 Mb). Additional analyses
(radiolabeled RFLP and quantitative PCR) conﬁrmed the mosaicism
of the duplication, deﬁned its value, and determined from which
allele the alteration arose. These techniques, which are not
routinely used for the characterization of genomic anomalies
identiﬁed by array-CGH analysis, detected the duplication in the
fraction between 40 and 51% of blood cells.
The duplication identiﬁed in our patient involves SCN2A and
SCN3A genes.
SCN1A, SCN2A and SCN3A, a cluster of genes localized at 2q24.3,
encode the alpha subunits of three voltage gated sodium channels
(Nav1.1, Nav1.2, Nav1.3) expressed in the central nervous system.
Voltage gated sodium channels are also fundamental to the
generation and propagation of action potentials in the brain and
muscle cells. Mutations of these three genes have been described
in patients with seizure disorders including generalized epilepsy
with febrile seizures plus (GEFS+, OMIM no. 604233), severe
myoclonic epilepsy in infancy (SMEI or Dravet syndrome; OMIM
no. 607208), borderline SMEI (SMEB) and benign familial neonatal-
infantile seizures (BFNIS).
Duplications involving SCN genes on 2q24.3 chromosome have
been observed in only a few cases until now. Marini et al.10
reported on a family with classical Dravet syndrome and an
intragenic duplication of SCN1A. A duplication involving SCN2A,
SCN3A and the last exon of SCN1A was recently identiﬁed in a
patient with ‘‘familial neonatal seizures and intellectual disabili-
ty’’.11 Raymond et al.12 have, moreover, described a female patient
with neonatal-infantile epilepsy and a 2 Mb duplication at 2q24.3
including SCN1A, SCN2A and SCN3A.
In this report we described the ﬁrst case of an epileptic patient
with a genomic duplication involving SCN2A and SCN3A and
excluding SCN1A.
As missense, gain of function mutations of SCN2A and SCN3A,
leading to increased sodium current, have been previously
reported in patients with epilepsy,3,4,13 duplication of these two
genes could potentially result in an increased expression of their
M. Vecchi et al. / Seizure 20 (2011) 813–816816transcript with subsequent increased sodium current and neuronal
excitability.
The other genes included in the duplication with a possible role
in the pathogenesis of neurological anomalies are KCNJ3,
KIAA1189, TANC1, TBR1, SLC4A10, KCNH7 and COBLL1. All these
genes have been shown to be expressed in the brains of humans
and experimental animals. In particular, SLC4A10 is a sodium
bicarbonate transporter gene and was recently found to be
disrupted in a balanced reciprocal translocation t(2;13)(q24;q31)
or deleted in patients with seizures and mental impairment.14,15
In conclusion, the array-CGH analysis is mandatory for children
presenting with epilepsy and psychomotor retardation even
without dysmorphisms or other clinical features suggesting a
speciﬁc genetic/epileptic syndrome. The analysis must neverthe-
less be performed taking into account the possibility of a
mosaicism (i.e. analyzing DNA extracted from several tissues
and conﬁrming the obtained results with different techniques).
Moreover, molecular analysis of SCN2A and SCN3A genes
should be performed in those children with no features of any
speciﬁc epileptic syndrome described in the literature.
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